HistoSonics, Inc.

Charles Nahabedian is hardly on an island when he professes his firm belief that artificial intelligence (AI) is going to dramatically change and improve healthcare. Where he is a bit of an outlier, however, is when he stated that the technology is not ready for such high praise and that significant work is still needed to confirm its true effectiveness for medtech from both a clinical and business perspective. “AI is still in the early stages, and while at this time it has made useful suggestions, its output has had errors in general,” said Nahabedian, CEO and co-founder at VK Digital Health, a technology company based in Bethesda, MD, that develops tele-diagnostic platforms for remote healthcare management. “In the near term, I think AI will help in the more rudimentary analyses, alternatives, and recommendations. It is going to be more successful sooner in those areas that don't impinge upon a physician's decision-making process. And it will take an astute businessperson to decipher AI output, including decisions and recommendations.” His thoughts on the potential of AI and where it might lead are indicative of what appears to be a compelling year on the horizon for the industry and original equipment manufacturers (OEMs), as advancing technology is expected to have a significant impact on what is being widely forecasted to be a time of robust medtech growth, increased revenues, and a viable investment market. According to various experts in the field who recently spoke with MD+DI , expectations for 2026 include a more strategic pathway to M&A activity, more companies entering into IPOs, and a focus on the development of more data-enabled and AI-enabled diagnostic devices. In the end, it very well may be those organizations that succeed in the advancement of AI that see the most success as these types of technologies become more lucrative with more reliability. “We are seeing a full-throttle approach from the market in the race to integrate AI into their businesses,” said Maria Palombini, the healthcare and life sciences global practice lead at IEEE Standards Organization, a non-profit organization that assists industry stakeholders in establishing global technology standards. “And there are different reasons behind that. Many publicly listed companies do it to show that they’re achieving innovation. Others are doing it because there is an opportunity to elevate the offerings among their products and services. These are all valid approaches and reasons, but the reality is that it's still really early for AI. Just because we have a market hype wave running towards it, we haven't been able to validate the results yet.” Advancing towards more appropriate AI From a high-level view, medtech is positioned to be a “success story,” with industry revenue growth estimated to be 6%  to 7% for 2025 after recording an annual tally of $584 billion in 2024, according to a recently released Pulse of the Industry Report produced by Ernst & Young (EY) LLP, a global organization that provides consulting and other services. Still, the medtech industry, like many others, presents a complex picture to assess due in part to such external influences as global tariffs and supply chain management, said John Babitt, global medtech leader at EY and one of the study’s authors. “This year has been a year of some uncertainty with respect to tariffs and the supply chain in general,” he said. “There was a lot of turbulence early on, but it seems like companies have really figured out how to navigate.” The integration of AI has been key to that, both from a “front office” perspective for client-facing purposes and from “back office” management of operations and internal support functions, said Babitt. “Companies are approaching things a little bit differently depending on their own situations, but one of the things that we’ve highlighted in our report is that there’s a real multifunctional approach to dealing with tariffs,” he said. “Companies are not just viewing this as a ‘tax issue.’ They’re looking at contracting, they’re looking at pricing, they’re looking at how they organize their supply chain. And they’re using AI and technology to better align demand with their internal supply.” On the front office, side, AI is being incorporated in a multitude of areas — namely in radiology, where most of the approvals from FDA have been granted, according to Babitt. “This field has experienced a lot of growth in AI, particularly in reading scans, interpreting scans, being able to provide more feedback to clinicians, and improving workflow within the hospital,” he explained. “But we’re also seeing AI having a role in areas like spine and/or cardiac that are really trying to create a more holistic ecosystem with their AI. I think we'll continue to see this evolution as well.” John C. Riddle, managing director at Brown Gibbons Lang & Company, an independent investment bank and financial advisory firm, said the ubiquitous nature of AI has already placed an emphasis on the need to focus development efforts on technology that introduces something truly innovative to differentiate from the crowd and advance business stature. “AI is already everywhere, and anybody that's not thinking about it relative to their business and business model needs to start to incorporate that into the strategy,” he said. “If you've got a solution that is AI-enabled, it is addressing a market, and you're going to change the paradigm — there’s capital available to that at relatively high values, generally speaking.” At VK Digital Health, an organization that operates as a Software as a Service (SaaS), AI has become integrated with the intention of augmenting what the medical team and patients need to know as opposed to attempting to replace the physician altogether. Nahabedian said there are plans to investigate the utilization of generative AI to be added to the SaaS, but any potential enhancements will be carefully and comprehensively vetted. “ The other place AI might be helpful is in the area of collecting data from the patient to more quickly reach conclusions as to certain vital signs or other measurements of health,” Nahabedian said. “There's potential there, but vendors are going to have to initially use output as advice to the doctor. AI can better examine results, compare them with historical standards, and illuminate the information that it finds for the physician. And I think you'll see a lot more of that.” Nahabedian advises that industry professionals exercise caution when considering the use of AI for marketing and other business-related communications. “We have found that AI has errors, and if you're not an effective editor for accuracy, the recipient is going to see errors and assume that the organization doesn't understand them, that the content is clearly created by a machine, and that it has no value.” The most influential benchmarks as more applications and devices delve into AI will likely be validation of results and responsible integration, said Palombini. “Being able to validate results is currently a challenge for everybody,” she said. “That doesn’t mean that what is being done today is wrong, it’s just the nature of dealing with a new technology being inserted into our system.” As integrated planning in general becomes more common throughout the industry, medtechs can expect to see an enhanced capability to predict demand, inventory, and capacity needs en route to better managing materials, vendor networks, distribution planning, and production and operational scheduling, according to the EY report. Across the industry, leading companies are increasingly developing differentiated, innovation-led models that help move to a higher-growth trajectory relative to their peers, the report claims, while suggesting that improved data and AI tools to optimize supply chains and operations more broadly will be a key differentiator. Strategic approaches to M&A activity With mergers and acquisitions (M&A) costing a reported total of $38.8 billion for 2025, the rate of M&A activity remains below historical averages, according to the EY report. However, an 11% increase has occurred in the average size of these deals, which at $497 million, also stands as a 72% increase in the average rate of transaction. These figures are part of signaling an agenda to be more strategic about committing to M&A investments as opposed to reacting to general market trends, said Riddle. “It’s less driven by market conditions versus the land of the old-school strategic M&A — meaning that a transaction is going to happen if there is a strategic fit,” he said. “It’s not just about being in a hot market where anything sells. For traditional instrument reagent models that are focused on a given disease state, getting to a transaction at the right value needs to fit a given larger global strategic strategy. They have to want to be in that disease state and have the capability. There’s a great amount of interest with OEMs and solutions providers who are focused on oncology, diagnostics, and digital and AI. Decidedly more investment and higher relative multiples are being assigned in that space. But there are other areas where it’s selective and driven by strategic imperative versus just playing the growth trend in a space.” At Gentell Inc., a global, vertically-integrated medical company based in Yardley, PA, that specializes in advanced wound care products and services, David Navazio, president and chief executive officer, says that he is fielding inquires related to M&A at a higher rate recently than he has compared to the last few years in the wound care sector, which he attributes to a track record of sustainability that carries a lot of weight in the present given ongoing global economic uncertainty. “We are seeing a lot of interest in companies that are already existing, and not so much in startups,” said Navazio, who launched his organization in 1994 and has grown it into what he and his stakeholders define as one of the largest vertically integrated wound care companies in the world, with five manufacturing plants on four continents. “The real money, the private equity money, the investment funds, and the IPOs — they're going to established companies with a good track record. And they're bidding them up.” Still, the industry overall has experienced a surge in venture capital financing. Another important aspect to M&A interest today is scalability, said Navazio, with which he sees a direct correlation to successful and verifiable integration of AI. “When we look at scalability, there has to be an ability to grow outside the reach of medical professionals,” he said. “You need to make sure that you have a program that can get patients treated wherever they are, whenever they are. And that’s where AI and a lot of your technology comes in. A component of the company needs to be able to take the evidence-based data and have a way of making business decisions — as long as it's verifiable and evidence-based.” New Influx of IPOs The unofficial drought of IPOs in medtech can be deemed over, explained Babitt. “Over the last year, we’ve had approximately a half-dozen medtech IPOs after not having any in the last approximately three years. There was a lot of pent-up demand. There are a multitude of companies that are now either at that ‘magic number’ of $40 million or $50 million of revenue run rate or well in excess of that rate. I've never seen as many $100 million rounds of financing as what we have seen this year. And to that extent, now we’re even seeing $200 million rounds. I would expect to see a robust set of companies that will either try the IPO route or run a dual-process route.” As evidence of this, Babitt points to a $250 million raise by HistoSonics, Plymouth, MN, in the fall that followed an acquisition completed a few months prior, as well as Boston Scientific’s acquisition of Nalu Medical, Carlsbad, CA, in October. “When companies are raising this kind of capital, it does ultimately set a precedent to get to an IPO sooner rather than later,” said Babitt. “I think we’ll see continued access to the public markets as long as the window stays open, which, hopefully, the solving of the government shutdown and the Securities and Exchange Commission back at work will put things on trajectory. Because the first quarter of the year is usually an opportune time from an IPO perspective. We certainly expect quite a few companies to look at the public markets if they can get their documents reviewed by then. I would expect to see a robust set of companies either try the IPO route or run a dual-process route.” David Hochman, CEO at Orchestra BioMed, New Hope, PA, a device technology company that specializes in late-stage clinical development for conditions including hypertension and artery disease, believes the upcoming year will be marked by IPO action. “I think 2026 has the potential to be a strong year in the public capital markets for medtech and medical devices, both in terms of appreciation of value for large and mid-cap, as well as for small-cap,” he said. “Predominantly, companies that have waited a long time have had to secure additional private investment to become that target profile that is so typical. When you’re a mature, approved, commercial-stage company that’s generating and growing revenues with attractive products — that’s difficult to do. We haven't really seen the markets open consistently, even for those companies. But I'm optimistic that in 2026, that should happen. What’s so interesting is that so much of the smaller companies that can get public and can raise capital in the public capital markets, by contrast, are truly development-stage companies that are developing products in the clinic or even earlier. And that's always the interesting contrast between the device industry and the public capital market and the biopharm industry.” Tariffs & trade The intricacies of global trade policy have become an area where any organization across the medtech spectrum has had to rapidly broaden its education to appropriately understand how all products could be impacted by tariffs, when this is traditionally not a required domain of technical expertise, according to EY’s analysis. Many companies are reportedly exploring the potential of creating “cross-functional tariff task force” groups and governance strategies to evaluate the impact of current and potential tariffs through scenario analysis, identifying mitigation plans, and benchmarking against competitor activity. These specialized task forces could also help to identify tariff mitigation actions across the supply chain, tax and trade, and commercial and government affairs to assist companies in prioritizing by impact and speed to value. “As we exit the year, companies feel a lot more confident that they at least have a plan for dealing with tariffs,” Babitt said.

近日，乐城先行区内树兰（博鳌）医院重磅发布了“治疗肝癌的超声组织碎化术（Histotripsy）HistoSonics Edison系统”。该设备由HISTOSONICS, INC.研发生产、杭州艾愈医疗科技有限公司引进。这一全球首个获批的Histotripsy设备，为国内肝癌患者带来了无创、高效的全新治疗选择，无需远赴海外即可同步享受国际顶尖医疗技术。 技术原理 超声组织碎化术（Histotripsy）是一种革命性的肿瘤治疗技术，其核心原理在于利用高强度、极短脉冲的超声波，在肿瘤内部精准聚焦并产生微小气泡云。这些气泡会在瞬间快速形成并破裂，释放出强大的机械力，从而直接破坏和液化癌细胞，实现 “物理碎瘤” 的效果。 与传统治疗技术不同，该技术全程不依赖热能，不穿透皮肤，不接触病灶。 特点和优势 2023年10月，HistoSonics Edison系统获得美国FDA批准，用于治疗肝脏肿瘤，成为首个在全球获批的Histotripsy设备。 该系统以机器人手臂为执行主体，结合CT与实时超声导航，实现三维靶向；医生只需在屏幕上设定区域，系统便能自动调整焦点、能量与路径，完成治疗。 特点&优势: ●完全无创，不需要穿刺，不产生热伤害；   ●只需一次治疗，过程约15到20分钟；  ●无已知的辐射相关毒性，副作用非常小；   ●目前的临床数据显示它的肿瘤局部控制率很高。 为让国内肝癌患者第一时间享受到这一国际前沿技术，树兰（博鳌）医院正式引进HistoSonics Edison系统。未来，树兰（博鳌）医院将持续依托自身的医疗资源，为患者提供更高效、安全、优质的治疗服务。 树兰（博鳌）医院挂号预约电话： 4001289991（工作日8:30-12:00，14:00-17:30） “乐”享世界医疗，“城”就健康梦想 更多相关信息 请关注“乐城发布”公众号 咨询电话：4000-118-118 来源：树兰博鳌医院 审核：何颖 编辑：袁昌佑

根据动脉智库不完全统计，2025年10月，全球医疗健康领域共发生182起融资事件（不包括IPO、定向增发等），披露融资总额约59.77亿美元（约426.63亿人民币）。其中，国内市场共发生67起融资事件，披露融资总额约7.43亿美元；海外市场共发生115起融资事件，披露融资总额约52.34亿美元。 01 2025年5月-2025年10月全球医疗健康产业融资事件对比 从交易金额、融资事件数量及新兴领域专注度等方面环比2025年9月全球医疗健康产业的投融资情况，2025年10月全球医疗健康产业融资事件数略有上升，约2.82%；但融资总额断崖式下跌，达41.25%。 大额融资事件方面，本月共发生16起过亿美元事件，累积融资金额达31.43亿美元。其中有14起发生在海外地区，2起发生在国内。这16家企业分别是：肥胖和相关疾病疗法研发商Kailera Therapeutics、药物偶联物研发商Tubulis、心血管药物开发商Kardigan、机器人辅助声波疗法研发商HistoSonics、医学人工智能技术研究商OpenEvidence、免疫学疾病和癌症疗法开发商Electra Therapeutics、自身免疫性疾病领域创新疗法研发商Expedition Therapeutics、罕见出血性疾病治疗药物研发商Hemab、痛风药物研发商Arthrosi Therapeutics、非激素口服治疗药物研发商Veradermics、抗体药物偶联物研发商Adcytherix、再生医学技术研究商Pelage Pharmaceuticals、中草药种植和研发商华榄基因、放射性药物研发商纽瑞特医疗、脑监测技术研究商CoMind以及免疫治疗新药研发商Nilo Therapeutics。 02 2025年10月全球医疗健康产业细分领域融资情况 全球医疗健康产业细分领域融资方面，相较于器械与耗材、数字健康、医疗服务和医药商业，生物医药的融资规模在10月处于主导地位，共发生74起融资事件，占全领域的40.66%，融资金额约40.91亿美元，占全领域的68.45%。 值得一提的是，新药研发商Kailera Therapeutics完成6亿美元B轮融资，一举拿下本月融资榜首。Kailera Therapeutics正在开发一系列广泛、先进且具有差异化的临床阶段注射剂与口服疗法，用于治疗肥胖症。该公司进展最快的候选药物KAI-9531（在中国以HRS9531为研发代号推进），是一款注射用GLP-1/GIP双受体激动剂，已在中国肥胖症临床试验中取得积极结果，本次融资所得款项将支持该药在年底前进行全球3期临床试验。Kailera Therapeutics还在推进多元化管线布局，涵盖多种作用机制与给药途径。 03 2025年10月全球医疗健康产业-融资大事件 罕见出血性疾病治疗药物研发商Hemab获得1.57亿美元C轮融资，以推进服务不足的出血性疾病的下一代治疗方法 2025年10月27日，罕见出血性疾病治疗药物研发商Hemab获得1.57亿美元C轮融资，由Sofinnova Partners领投，一家大型多头全球资产管理公司大量参投，其他新投资者也参与其中，包括一家大型全球主权财富基金和Avoro Capital Advisors，以及现有投资者RA Capital Management、Novo Holdings、Access Biotechnology、Deep Track Capital、HealthCap、Invus、Avoro Ventures、Maj Invest Equity和Rock Springs Capital。额外的资金使Hemab能够将更多候选新药推进临床开发，HMB-003预计将于2026年上半年发布。这一扩大的产品线加强了Hab致力于开发涵盖高未满足需求出血性疾病的综合治疗解决方案的承诺。 免疫学疾病和癌症疗法开发商Electra Therapeutics获得1.83亿美元C轮融资，开发靶向SIRP抗体 2025年10月22日，免疫学疾病和癌症疗法开发商Electra Therapeutics获得1.83亿美元C轮融资。本轮融资由Nextech和EQT Life Sciences共同领投，新投资者赛诺菲、HBM Healthcare Investments和Mubadala Capital以及现有投资者OrbiMed、Redmile Group、New Leaf Venture Partners、Westlake BioPartners、Cormorant Asset Management、Blue Owl Capital和RA Capital Management也参与其中。融资收益将用于资助ELA026在继发性噬血细胞淋巴组织细胞增生症（sHLH）中的全球关键2/3期研究，这是一种死亡率高、缺乏治疗选择的恶性炎症疾病。 医学人工智能技术研究商OpenEvidence宣布完成2亿美元C轮融资 2025年10月21日，医学人工智能技术研究商OpenEvidence于10月20日宣布完成2亿美元C轮融资，投后估值达到60亿美元。本轮融资由GV领投，红杉资本、黑石集团、Kleiner Perkins、Thrive Capital等知名机构参投。公司为医生群体打造可以信赖的医疗版ChatGPT，提供专业医疗信息的搜寻、整理和分析，超过40%的美国医生每天都会使用。 聚焦药食同源黄金赛道，华榄基因完成8亿元天使轮融资 2025年10月20日，广西华榄基因医药集团有限公司正式宣布完成8亿元天使轮融资，据悉，本轮融资将主要用于核心药材的规模化种植基地建设、现代化加工产线的升级、药食同源产品的深度研发与创新，以及全国市场销售渠道的初步搭建。 脑监测技术研究商CoMind完成1.025亿美元融资 2025年10月20日，脑监测技术公司CoMind宣布完成1.025亿美元融资，由Plural领投，现有投资者Angelini Ventures、LocalGlobe、Octopus Ventures、Crane、Backed VC和Entrepreneurs First参与。公司表示，新资金将用于拓展研发与制造合作，并支持团队扩张，以加快产品商业化进程。CoMind的目标是打造一种能够实时反映脑部血流灌注、脑自调节功能与颅内压状态的非侵入式监测系统，帮助临床医生在多种场景下做出更及时、精准的决策。 机器人辅助声波疗法研发商HistoSonics获得2.5亿美元融资 2025年10月16日，机器人辅助声波疗法研发商HistoSonics获得2.5亿美元融资，由其新的所有权集团领导，包括其他投资者Thiel Bio和Founders Fund等。此次融资将支持HistoSonics的Edison系统向新的全球市场进行持续的商业扩张，加速全身新的临床适应症，并加强下一阶段增长的运营能力。 非激素口服治疗药物研发商Veradermics获得1.5亿美元C轮融资，用于口服生发治疗 2025年10月16日，非激素口服治疗药物研发商Veradermics获得1.5亿美元C轮融资。本次融资由SR One领投，新投资者Viking Global Investors、Marshall Wace、Invus、abrdn Inc.、Columbia Threadneedle Investments、Infinitium、LifeSci Venture Partners以及现有投资者包括Longitude Capital、Suvretta Capital Management、Surveyor Capital和其他未公开的投资者参投。融资所得款项旨在推进和完成正在进行的3期试验，如果临床数据支持，则随后向美国食品药品监督管理局提交新药申请以供VDPHL01。 抗体药物偶联物研发商Adcytherix获得1.22亿美元A轮融资，开发下一代ADC药物 2025年10月16日，抗体药物偶联物研发商Adcytherix获得1.22亿美元A轮融资，由Bpifrance领投，作为Large Venture和InnoBio投资战略的一部分，由Kurma Partners、Andera Partners和Angelini Ventures以及Surveyor Capital和aMoon等国际顶级投资者组成的财团共同参与。所有创始人和现有投资者也参与了本轮融资。融资将Adcytherix定位为更有前景的ADC玩家之一，利用新型有效载荷类别和经验丰富的团队为患者提供有针对性的癌症治疗。 药物偶联物研发商Tubulis获得3.61亿美元C轮融资，开发下一代ADC药物 2025年10月15日，药物偶联物研发商Tubulis获得3.61亿美元C轮融资。本轮融资由Venrock Healthcare Capital Partners领投，其他新投资者Wellington Management和Ascenta Capital也参与其中。支持C轮融资的现有投资者包括Nextech Invest、EQT Life Sciences、Frazier Life Sciences、Andera Partners、Deep Track Capital、Bayern Kapital、Fund+、High-Tech Gründerfonds (HTGF)、OCCIDENT和Seventure Partners。C轮融资的收益将用于将Tubulis的领先抗体偶联药物（ADC）候选物TUB-040的临床开发扩展到早期治疗线和其他肿瘤适应症。 再生医学技术研究商Pelage Pharmaceuticals宣布完成1.2亿美元B轮融资 2025年10月15日，再生医学技术研究商Pelage Pharmaceuticals宣布完成1.2亿美元B轮融资，由ARCH Venture Partners和GV共同领投，Main Street Advisors、Visionary Ventures和YK Bioventures等现有投资者参投。这笔融资将支持Pelage的牵头项目PP405的持续推进，这是一种旨在重新激活休眠毛囊干细胞的局部小分子，为经历脱发的男性和女性提供潜在的一流方法。 肥胖和相关疾病疗法研发商Kailera Therapeutics宣布完成6亿美元B轮融资，以进一步推进用于治疗肥胖症的下一代疗法管线 2025年10月14日，肥胖和相关疾病疗法研发商Kailera Therapeutics宣布完成6亿美元B轮融资，由Bain Capital Private Equity领投，其他新投资者包括领先的共同基金和投资者，包括Adage Capital Management LP、CPP Investments、Invus、Janus Henderson investors、Perseverance Capital、Qatar Investment Authority、Royalty Pharma、Surveyor Capital、T. Rowe Price Associates, Inc.。Kailera的现有投资者Atlas Venture、Bain Capital Life Sciences、RTW Investments和Sirona Capital也参与了本轮融资。所得款项支持KAI-9531（一种具有潜在同类最佳减肥效果的注射GLP-1/GIP双重激动剂）在年底前推进全球3期试验。 心血管药物开发商Kardigan筹集2.54亿美元B轮融资，推进个性化心血管药物的后期阶段产品组合 2025年10月14日，心血管药物开发商Kardigan筹集2.54亿美元B轮融资，新投资者包括Fidelity Management & Research company和T. Rowe Price Investment Management, Inc.，以及ARCH Venture Partners和Sequoia Heritage的再次支持。该公司将利用B轮融资的资金推进其互补候选药物管道，以针对特定类型的扩张型心肌病（DCM）、钙化性主动脉瓣狭窄（CAVS）和急性严重高血压（ASH）的潜在驱动因素。 自身免疫性疾病领域创新疗法研发商Expedition Therapeutics完成1.65亿美元A轮融资，推进下一代DPP1抑制剂用于慢性阻塞性肺病的治疗 2025年10月9日，自身免疫性疾病领域创新疗法研发商Expedition Therapeutics完成1.65亿美元A轮融资， 由Sofinnova Investments和Novo Holdings共同领投，Forbion、Dawn Biopharma、Adage、Balyasny、Logos Capital、Sanofi Ventures以及现有投资者BVF Partners和Venrock Healthcare Capital Partners参投。资助将EXPD-101推进EXPD-101，这是一种2期就绪、每日一次的口服DPP1抑制剂，具有一流的潜力，用于治疗慢性阻塞性肺病和其他广泛的中性粒细胞驱动疾病的全球开发计划。 纽瑞特医疗完成8亿元D轮融资，“核素+核药”模式吸引多家资深投资机构，凯乘资本担任牵头财务顾问 2025年10月9日，成都纽瑞特医疗科技股份有限公司完成约8亿元人民币D轮融资。本轮融资由深创投、人保资本联合领投，中核基金、阿斯利康中金医疗产业基金、中启资本、广东中医药大健康基金、核力高新、湖南财信产投及空港创投多家知名投资公司和金融机构联合出资，老股东泸州星空、新投华策、榕投基金也持续加码，凯乘资本担任牵头财务顾问。公司在研多款创新产品。包括钇[90Y]炭微球注射液、核素偶联生物单抗/多肽等产品。主要用于诊断和治疗肝癌、胰腺癌、淋巴癌、甲状腺癌、前列腺癌、肺癌等高发癌症。 免疫治疗新药研发商Nilo Therapeutics完成1.01亿美元A轮融资，推进一类针对免疫疾病神经回路的新药物 2025年10月8日，免疫治疗新药研发商Nilo Therapeutics正式启动，并获得1.01亿美元的A轮融资。本轮融资由The Column Group、DCVC Bio和Lux Capital领投，Gates Foundation和Alexandria Venture Investments提供额外支持。在公司成立之际，Nilo Therapeutics任命Kim Seth博士为首席执行官兼董事会董事。该公司由知名科学家Charles Zuker、Ruslan Medzhitov和Steve Liberles创立，旨在将神经免疫学的突破转化为创新疗法。这笔资金将用于在纽约市建立实验室，扩充其跨学科研发团队，并推进临床前项目。Nilo Therapeutics的方法通过靶向神经回路来中枢性调节免疫平衡，为免疫调节提供了一种全新的策略。 痛风药物研发商Arthrosi Therapeutics完成1.53亿美元E轮融资，推进pozdeutinurad（AR882）的临床开发 2025年10月8日，后期阶段生物技术公司Arthrosi Therapeutics宣布完成1.53亿美元E轮融资，由Prime Eight Capital Limited领投，CR Biotech、HighLight Capital、HM Venture Partners、ReliantTech Limited和现有股东参与，财务顾问信息未提及。该公司正在开发潜在的同类最佳、高效和选择性的下一代URAT1抑制剂pozdeutinurad（AR882），以降低痛风患者血清尿酸盐水平。Arthrosi计划利用这笔融资完成其核心项目pozdeutinurad的临床3期REDUE 1和REDUCE 2研究，评估其治疗痛风和痛风石性痛风的能力，两项3期临床试验现已全部注册，预计2026年第二季度报告关键数据。 欢迎立刻扫描二维码添加小助手获取完整月报并申请免费试用数据库，添加过请主动询问：